Merrimack Pharma to Launch Stock, Convertible Notes Issues

Before you go, we thought you'd like these...
Before you go close icon

Merrimack Pharmaceuticals is gearing up for a double dose of fund-raising. The company announced that it will concurrently float both a common stock and a convertible notes issue in a public offering. In the former, Merrimack will offer $50 million worth of shares, while the latter will take the form of $75 million in senior notes maturing in 2020. Additionally, the company expects that it will grant its underwriters a 30-day purchase option for up to an additional $7.5 million worth of common shares and $11.25 million of the convertible notes.

The exact per-unit price of both securities will be hashed out between Merrimack and the underwriters.

The company said it plans to use the proceeds of the issues to fund commercial efforts for its goods, as well as product development, research, and "general corporate purposes."


JPMorgan Chase unit J.P. Morgan Securities and Bank of America's Merrill Lynch are the joint book-running managers of the issue.  

At the moment, Merrimack has just over 96 million shares outstanding, and its most recent closing stock price was $6.99 per share.

The article Merrimack Pharma to Launch Stock, Convertible Notes Issues originally appeared on Fool.com.

Fool contributor Eric Volkman has no position in any stocks mentioned. The Motley Fool recommends Bank of America and owns shares of Bank of America and JPMorgan Chase. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Read Full Story

Want more news like this?

Sign up for Finance Report by AOL and get everything from business news to personal finance tips delivered directly to your inbox daily!

Subscribe to our other newsletters

Emails may offer personalized content or ads. Learn more. You may unsubscribe any time.

From Our Partners